Pfizer announces Chief Financial Officer transition
- Pfizer (NYSE:PFE) announced that Chief Financial Officer Dave Denton will step down from his role on August 15, 2026.
- Denton is leaving the pharmaceutical industry to pursue a professional opportunity in the consumer goods sector.
- Cecile Guegan, currently Senior Vice President, Finance, Global Biopharmaceutical Business, has been appointed as interim CFO, effective August 16, 2026.
Pfizer (NYSE:PFE) announced today that its Chief Financial Officer, Dave Denton, will depart the company on August 15, 2026, to accept a new position within the consumer goods industry.
The company has initiated a comprehensive search for a permanent successor and has named Cecile Guegan, a long-time Pfizer executive, to serve as interim CFO starting August 16, 2026.
"Dave has been a steady and trusted steward of Pfizer’s financial health, and we are grateful for his leadership, especially during some of the most important business transactions in our recent history," said Pfizer Chair and CEO Albert Bourla.
Denton expressed his confidence in the transition, stating, "Pfizer is in excellent hands, and I leave knowing the executive leadership team, now including Cecile as interim CFO, will continue to succeed."
Guegan brings over two decades of experience to the role, having led financial operations for Pfizer’s biopharmaceutical business and managing key enterprise initiatives, such as the 2024 integration of Seagen.
Pfizer remains focused on its strategic objective of delivering therapeutic solutions to patients worldwide while maintaining financial discipline under the new leadership transition.
